Wik B, Dale J
Department of Internal Medicine, Vest-Agder Central Hospital, Kristiansand, Norway.
Acta Med Scand. 1988;223(1):15-8. doi: 10.1111/j.0954-6820.1988.tb15759.x.
The effect of very early infusion of 1.5 X 10(6) U of streptokinase intravenously was studied in 29 patients with nitroglycerin-resistant chest pain and ST-segment elevation. Infarct size was estimated from maximal LD1 isoenzyme levels, and the diagnosis confirmed by CK-MB determination. Thrombolytic therapy was started within 1 hour of pain onset in 11 patients (group A), between 1 and 2 hours in 10 (group B), and later than 2 hours in eight patients (group C). Marked differences appeared between the groups. Thus, three patients in group A and one patient in group B did not develop infarction, all had critical LAD stenoses. Three patients in group C died in shock without bleeding. Further, the average maximal LD1 values in the 22 patients who survived their infarction differed significantly between the groups, and were 12.6, 19.1 and 36.2 mu kat/l in groups A, B and C, respectively. In conclusion, very early intravenous streptokinase infusion probably reduces myocardial necrosis, and possible prevents infarction in some patients.
对29例对硝酸甘油耐药且伴有ST段抬高的胸痛患者静脉注射1.5×10⁶U链激酶的极早期效果进行了研究。根据最大LD1同工酶水平估算梗死面积,并通过CK-MB测定来确诊。11例患者(A组)在疼痛发作后1小时内开始溶栓治疗,10例患者(B组)在1至2小时内开始,8例患者(C组)在2小时后开始。各组之间出现了明显差异。因此,A组有3例患者和B组有1例患者未发生梗死,均有严重的左前降支狭窄。C组有3例患者死于休克且无出血。此外,22例梗死存活患者的平均最大LD1值在各组之间有显著差异,A组、B组和C组分别为12.6、19.1和36.2微卡/升。总之,极早期静脉注射链激酶可能会减少心肌坏死,并可能在某些患者中预防梗死。